Biofilm is a viscous structure formed by the accumulation of bacteria. This structure can protect cells from outside influences. Because this protective layer is resistant to antibiotics, when the microbes contaminate the suture used in surgery or infect the urinary catheter, the biofilm formed has hazardous consequences. The dynamic process of biofilms establishes an important strategy to withstand and survive harsh environmental conditions and antimicrobial agents. It refers to a large number of bacterial aggregated membranes formed by bacteria adhering to the contact surface, secreting polysaccharide matrix, fibrin, and lipid-protein, etc. Biofilm formation and related infections are the keys to the success of the use of the insertable medical device.
The global biofilms treatment market size was stood at USD 1.59 Billion in 2019 and projected to reach USD 2.76 Billion by 2027, registering a CAGR of 6.82% during the forecast period, 2020-2027. The growth of the market can be attributed to the rising prevalence of chronic, surgical, and traumatic wounds and the growing incidence of burn injuries. Further, the increasing usage of bacteria for treating cancer through oral administration circumvents will spur the growth of the market. The surge in the growing prevalence of diabetes and the expanding population of an elder would impact the robust growth of the biofilms treatment market in future periods. Also, the increasing application for bacterial biofilms in device-related and other chronic infections grow will positively impact the biofilms treatment market.
The characteristics and resistance mechanisms of bacteria biofilm will help us treat the stubborn infections caused by the bacterial biofilm better and solve the problem of bacterial drug resistance. The growing usages of debridement, antimicrobials, and dressing technologies used to most efficiently suppress wound biofilm and encourage healing. These factors estimated to propel the growth of the global biofilms treatment market share in the coming years.
The burden of chronic diseases is rapidly growing globally. The four primary chronic disease prevention and treatment actions, strategically shifting from focusing on treating the disease from individuals to society. The cancer disease that seriously affects the health of people worldwide. WHO projected that, by 2020, chronic diseases expected accounting for almost three-quarters of deaths worldwide, and 75% of deaths due to stroke, 71% of deaths due to ischaemic heart disease, and 70% of deaths will occur due to diabetes in developing countries.
The World Health Organization also stated that the number of people in the developing world with diabetes would increase from 84 million in 1995 to 228 million in 2025. Globally, 60% of the burden of chronic diseases will occur in developing countries.
According to WHO, the estimated 1,80,000 deaths every year are caused by burns. Burns are devastating injuries, often resulting in significant morbidity, impairment of emotional well-being, and experienced quality of life. Also, the stressful immediate care burns often require long-term treatment with numerous outpatient visits and multiple reconstructive surgical procedures concomitant hospital stays.
Based on product, the global biofilms treatment market classified into debridement equipment, gauzes and dressing, grafts and matrices, wipes, pads, and lavage solutions, gels, ointments, and sprays. The gauzes and dressing will witness significant growth in the forecast period. It is primarily attributed to the ability of antimicrobial products to remove, prevent, and manage biofilms.
The debridement equipment will capture the highest revenue share in the forecast period due to it is the most effective means of removing and preventing biofilms and inspect wounds for biofilms.
Based on wound type, the global biofilms treatment market segregated into surgical and traumatic wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, burns & other open wounds. The surgical and traumatic wounds segment held a lucrative share in 2019 and projected to dominate the global biofilms treatment market by 2027. It is due to the increasing prevalence of diabetes and the growing number of surgical procedures performed.
The diabetic foot ulcers will capture lucrative in the forecast period owing to biofilms contribute to the chronic inflammatory changes in the wound bed.
Based on end-user, the global Biofilms Treatment market bifurcated into the hospital, ASCS, wound care centers, home care settings, and others. The hospital, ASCS, wound care centers segment estimated to lead the market by 2027 due to the surge in the development of hospitals in emerging centers and the rise in demand for a new treatment for chronic diseases like cancer and burn injuries.
The home care settings will grow with a significant rate during the forecast period owing to the increase in disposables levels in developing countries and the growing adoption of home settings treatment among consumers.
Based on geography, the global biofilms treatment market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America accounted for the largest market share in 2019. It is owing to the presence of significant market players, the growing incidence of chronic wounds, and the increasing healthcare expenditure in the region.
The Asia Pacific will witness a prominent share of the biofilms treatment market by 2027. It is due to the financial support of the government in the healthcare industry and spending expenditure by people for saving a life.
Companies such as Smith & Nephew plc, MiMedx Group Inc., ConvaTec Group plc, Coloplast A/S, Mölnlycke Healthcare AB, Organogenesis Holdings Inc, Integra LifeSciences Holdings Corporation, B. Braun Melsungen AG, PAUL HARTMANN AG, Medline Industries Inc., Acelity, Misonix, Zimmer Biomet Holdings Inc., Kerecis, Welcare Industries S.p.A, Medaxis AG, Pulsecare Medical, Arobella Medical LLC, Advancis Medical, RLS Global AB, Mil Laboratories Pvt. Ltd., Sanara MedTech Inc., Medicareplus International, Next Science Limited, and Aroa Biosurgery are the key players in the global biofilms treatment market.
By Wound Type